Kineta (Private) is a biotechnology company with expertise in innate immunity and immunology and a focus on IO, neuroscience and biodefense. Kineta signed 2 large early stage partnering deals in 2018 - $520M deal with Pfizer for its small molecule RIG-I immunotherapy that elicits a dual mechanism to turn cold tumors hot (tumor activity in checkpoint resistant tumors); and a $360M+ deal with Genentech for KCP506, a first in class a9/a10 Nicotinic Acetylcholine Receptor (nAChR) antagonist - preclinical, non-opioid for chronic pain. Kineta currently has a Ph 1 asset LHF-535 for the treatment of Lassa Fever that is wholly funded by Wellcome Trust (receive priority review voucher upon approval).
Phase l or ll, Pre-Clinical Stage
Anti-infectives, Antivirals, Immuno-Oncology, Immunotherapy, Pain
219 Terry Ave N.
Seattle, WA 98109
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Hamptons CEO Roundtable 2019
August 15, 2019